NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that the Company will be presenting on its advanced computational platform, which integrates physics-based molecular simulation and machine learning to accelerate drug discovery, at the upcoming conferences in May:
- NewYorkBio in New York City; CEO Ramy Farid will present at the first New York Emerging Biotech Company Showcase at the New York Stock Exchange on Monday, May 13 at 2 p.m. ET.
- NewYorkBio in New York City; Chief Biomedical Scientist Karen Akinsanya will join fellow pharma and biotech drug development leaders on a panel to discuss how data science and artificial intelligence are shaping the biopharma industry’s therapeutic pipeline at NewYorkBio's Annual Meeting on Tuesday, May 14 at 11 a.m. ET.
- Bank of America Merrill Lynch Healthcare Conference in Las Vegas; Senior Vice President Robert Abel will participate in a panel discussion entitled “How is AI changing the drug discovery paradigm?” on Tuesday, May 14 at 1 p.m. PT and will present on Thursday, May 16 at 10 a.m. PT.
- UBS Global Healthcare Conference in New York City; CEO Ramy Farid will present on Tuesday, May 21 at 11 a.m. ET.
Schrödinger has a substantial and growing global business, licensing its industry-leading computational platform to pharmaceutical, biotechnology, chemical, and electronics companies to accelerate R&D in both drug discovery and materials design. Schrödinger has built a robust pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger’s significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world. Visit schrodinger.com for more information.